Overview

Study Evaluating Venlafaxine ER in Adults With Panic Disorder

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Venlafaxine Hydrochloride